MORE VIDEOS
Udforsk mere
Brystkræft

Næste

Automatisk afspilning
Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
00:03:06
Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
3 Visninger . 08/09/23 administrator
CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
00:02:51
CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
3 Visninger . 08/09/23 administrator
The Importance of Collaboration in Treating CTCL (Chapter 7)
00:02:30
The Importance of Collaboration in Treating CTCL (Chapter 7)
3 Visninger . 08/09/23 administrator
The CTCL diagnosis journey
00:00:20
The CTCL diagnosis journey
7 Visninger . 08/09/23 administrator
Unmet needs for late-stage CTCL
00:01:10
Unmet needs for late-stage CTCL
3 Visninger . 08/09/23 administrator
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
00:01:16
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
4 Visninger . 08/09/23 administrator
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
00:01:35
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
4 Visninger . 08/09/23 administrator
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
00:08:49
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
12 Visninger . 08/09/23 administrator
Pre-clinical activity of tipifarnib in CTCL
00:02:12
Pre-clinical activity of tipifarnib in CTCL
6 Visninger . 08/09/23 administrator
Cerdulatinib yields 'encouraging' results in CTCL, PTCL
00:04:47
Cerdulatinib yields 'encouraging' results in CTCL, PTCL
4 Visninger . 08/09/23 administrator
CTCL 06 2017
02:28:08
CTCL 06 2017
2 Visninger . 08/09/23 administrator
Brentuximab vedotin for CTCL
00:02:30
Brentuximab vedotin for CTCL
2 Visninger . 08/09/23 administrator
Clonal evolution in patients with CTCL
00:02:24
Clonal evolution in patients with CTCL
4 Visninger . 08/09/23 administrator
RESMAIN: HDAC inhibitor resminostat for CTCL
00:01:23
RESMAIN: HDAC inhibitor resminostat for CTCL
3 Visninger . 08/09/23 administrator
Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
00:13:18
Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
2 Visninger . 08/09/23 administrator
Unmet needs and upcoming therapies in CTCL
00:03:34
Unmet needs and upcoming therapies in CTCL
2 Visninger . 08/09/23 administrator
Novel Therapies for CTCL - Andrei Shustov, MD
01:00:41
Novel Therapies for CTCL - Andrei Shustov, MD
3 Visninger . 08/09/23 administrator
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
00:01:02
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
4 Visninger . 08/09/23 administrator
Unmet needs and upcoming therapies in CTCL
00:03:34
Unmet needs and upcoming therapies in CTCL
4 Visninger . 08/09/23 administrator

CTCL Roundtable - Dr. Porcu

1 Visninger • 08/09/23
Del
Indlejre
administrator
administrator
Abonnenter
0

#Cancer #CTCL #lymphoma #raredisease

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning

Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
00:03:06
Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
3 Visninger . 08/09/23 administrator
CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
00:02:51
CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
3 Visninger . 08/09/23 administrator
The Importance of Collaboration in Treating CTCL (Chapter 7)
00:02:30
The Importance of Collaboration in Treating CTCL (Chapter 7)
3 Visninger . 08/09/23 administrator
The CTCL diagnosis journey
00:00:20
The CTCL diagnosis journey
7 Visninger . 08/09/23 administrator
Unmet needs for late-stage CTCL
00:01:10
Unmet needs for late-stage CTCL
3 Visninger . 08/09/23 administrator
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
00:01:16
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
4 Visninger . 08/09/23 administrator
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
00:01:35
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
4 Visninger . 08/09/23 administrator
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
00:08:49
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
12 Visninger . 08/09/23 administrator
Pre-clinical activity of tipifarnib in CTCL
00:02:12
Pre-clinical activity of tipifarnib in CTCL
6 Visninger . 08/09/23 administrator
Cerdulatinib yields 'encouraging' results in CTCL, PTCL
00:04:47
Cerdulatinib yields 'encouraging' results in CTCL, PTCL
4 Visninger . 08/09/23 administrator
CTCL 06 2017
02:28:08
CTCL 06 2017
2 Visninger . 08/09/23 administrator
Brentuximab vedotin for CTCL
00:02:30
Brentuximab vedotin for CTCL
2 Visninger . 08/09/23 administrator
Clonal evolution in patients with CTCL
00:02:24
Clonal evolution in patients with CTCL
4 Visninger . 08/09/23 administrator
RESMAIN: HDAC inhibitor resminostat for CTCL
00:01:23
RESMAIN: HDAC inhibitor resminostat for CTCL
3 Visninger . 08/09/23 administrator
Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
00:13:18
Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
2 Visninger . 08/09/23 administrator
Unmet needs and upcoming therapies in CTCL
00:03:34
Unmet needs and upcoming therapies in CTCL
2 Visninger . 08/09/23 administrator
Novel Therapies for CTCL - Andrei Shustov, MD
01:00:41
Novel Therapies for CTCL - Andrei Shustov, MD
3 Visninger . 08/09/23 administrator
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
00:01:02
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
4 Visninger . 08/09/23 administrator
Unmet needs and upcoming therapies in CTCL
00:03:34
Unmet needs and upcoming therapies in CTCL
4 Visninger . 08/09/23 administrator